Ariosa Diagnostics (AROS) Files $69M IPO

Ariosa Diagnostics, Inc. (Nasdaq: AROS) filed an amended registration with the U.S. Securities and Exchange Commission for an initial public offering of its Common Stock. The proposed maximum offering price is $69 million. The company plans to list on the Nasdaq Global Market under the symbol AROS.

The offering is being made through J.P. Morgan, Citigroup, Leerink Partners, and William Blair.

The company stated: Harmony is available in over 90 countries, including the United States, and has experienced rapid adoption since its commercial launch in March 2012. Our revenue was $12.0 million in 2012, and $53.3 million in 2013. Our net loss was $21.9 million in 2012 and $2.4 million in 2013. In 2013, approximately 25% of our revenue was generated in international markets.

Ariosa Diagnostics is a global commercial-stage molecular diagnostics company focused on improving overall patient care by developing and delivering innovative, affordable and widely-accessible genetic testing.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• MED-X, INC (MXRX) Announces 2.125M Share IPO at $4/sh
• TransCode Therapeutics (RNAZ) Prices 2M Share Offering at $3.50/sh
• Mondee Holdings (MOND) Prices 5.25M Share Secondary Offering at $10/sh